A securities fraud class action lawsuit has been filed against Zoetis Inc., and investors who purchased or acquired Zoetis securities between January 14, 2025 and May 6, 2026 have until July 27, 2026 to seek lead plaintiff status. The lawsuit, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., was filed in the United States District Court for the Southern District of New York and alleges that the company made materially false or misleading statements and failed to disclose that prescription growth for Librela was weakening after FDA safety warnings, Simparica Trio was losing market share to a lower-priced competitor, and dermatological products Apoquel and Cytopoint were also losing market share. On May 7, 2026, Zoetis reported a significant decline in its Companion Animal business, causing its stock price to fall 21.5%. The law firm Kessler Topaz Meltzer & Check, LLP is informing investors of their legal rights and encourages them to contact the firm for a free case evaluation.
Zoetis IncSecurities fraud class action lawsuit alleging false statements about weakening Librela prescription growth and market share losses for Simparica Trio, Apoquel, and Cytopoint
ServiceNow Inc